Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Rx Card "Rejected" By Seniors, Senate Dems Say, Citing Low Enrollment

This article was originally published in The Pink Sheet Daily

Executive Summary

Sen. Daschle says only about 500,000 out of 41 mil. eligible seniors have enrolled in discount cards marketed to the general Medicare population. Senate Democrats believe low response to card will provide impetus for legislation allowing drug importation and government negotiation of Medicare drug prices.

You may also be interested in...



CMS Report Highlights Drug Card Savings For Chronic Conditions

In an analysis of the best drug card prices for 23 drugs used to treat nine chronic conditions, CMS found that savings range from 10% to 75%, when compared to the national average retail monthly price. Treatment savings can also be attained with drug cards offering less-than-optimal discounts, the report says.

CMS Report Highlights Drug Card Savings For Chronic Conditions

In an analysis of the best drug card prices for 23 drugs used to treat nine chronic conditions, CMS found that savings range from 10% to 75%, when compared to the national average retail monthly price. Treatment savings can also be attained with drug cards offering less-than-optimal discounts, the report says.

Medicare Rx Cards Struggling Because Pharma Not Providing "Significant Discounts" – WellPoint

Without "dramatic change" in manufacturer prices by the 2006 Medicare Rx benefit, "there's going to be hell to pay," WellPoint VP says.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel